Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization

Anesthesia and Analgesia

Volumn 111, Issue 6, 2010, Pages 1490-1496

  Jooste, E H ^a   Muhly, W T ^a   Ibinson, J W ^a   Suresh, T ^a   Damian, D ^a   Phadke, A ^a   Callahan, P ^a   Miller, S ^b   Feingold, B ^a   Lichtenstein, S E ^a   Cain, J G ^a   Chrysostomou, C ^c   Davis, P J ^a  

^a Transplant Division   (United States)

^b Department of Pediatric Cardiology   (Japan)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; FENTANYL; ISOFLURANE; MIDAZOLAM; NITROUS OXIDE; OXYGEN; PROPOFOL; ROCURONIUM; SEVOFLURANE;

ARTICLE; CENTRAL VENOUS PRESSURE; CHILD; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; ENDOTRACHEAL INTUBATION; FEMALE; GENERAL ANESTHESIA; HEART CATHETERIZATION; HEART GRAFT; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART TRANSPLANTATION; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; THERMODILUTION;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; BLOOD PRESSURE; CARDIAC OUTPUT; CENTRAL VENOUS PRESSURE; CHILD; CHILD, PRESCHOOL; DEXMEDETOMIDINE; FEMALE; HEART CATHETERIZATION; HEART RATE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENOUS; MALE; PENNSYLVANIA; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; TIME FACTORS; VASCULAR RESISTANCE;

EID: 78650306268     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181f7e2ab     Document Type: Article

References (42)

1. Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, Vedio A, Singer M, Feneck R, Treacher D, Willatts SM, Grounds RM. Preliminary UK experience of dexmedeto-midine, a novel agent for postoperative sedation in the inten-sive care unit. Anaesthesia 1999;54:1136-42
2. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol 1988;150:9-14
3. McDonald T, Hoffman WE, Berkowitz R, Cunningham F, Cooke B. Heart rate variability and plasma catecholamines in patients during opioid detoxification. J Neurosurg Anesthesiol 1999;11:195-9
4. Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intrave-nous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992;77:1125-33
5. Peden CJ, Cloote AH, Stratford N, Prys-Roberts C. The effect of intravenous dexmedetomidine premedication on the dose re-quirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anaesthesia 2001;56:408-13
6. Munro HM, Tirotta CF, Felix DE, Lagueruela RG, Madril DR, Zahn EM, Nykanen DG. Initial experience with dexmedetomi-dine for diagnostic and interventional cardiac catheterization in children. Paediatr Anaesth 2007;17:109-12
7. Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth 2006;16:748-53
8. Carroll CL, Krieger D, Campbell M, Fisher DG, Comeau LL, Zucker AR. Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit J Hosp Med 2008; 3:142-7
9. Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993;78:813-20
10. Triltsch AE, Welte M, von Homeyer P, Grosse J, Genahr A, Moshirzadeh M, Sidiropoulos A, Konertz W, Kox WJ, Spies CD. Bispectral index-guided sedation with dexmedetomidine in in-tensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med 2002;30:1007-14
11. Rosen DA, Daume JT. Short duration large dose dexmedeto-midine in a pediatric patient during procedural sedation. Anesth Analg 2006;103:68-9
12. Barton KP, Munoz R, Morell VO, Chrysostomou C. Dexme-detomidine as the primary sedative during invasive proce-dures in infants and toddlers with congenital heart disease. Pediatr Crit Care Med 2008;9:612-5
13. Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology 1992;76:948-52
14. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003;98:428-36
15. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists: their pharmacology and therapeutic role. Anaesthesia 1999;54:146-65
16. Kamisaki Y, Ishikawa T, Takao Y, Omodani H, Kuno N, Itoh T. Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Res 1990;514:15-21
17. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002;283:R287-95
18. Mason KP, Zgleszewski SE, Prescilla R, Fontaine PJ, Zura-kowski D. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth 2008;18:393-402
19. Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergo-ing magnetic resonance imaging. Anesth Analg 2006;103:63-7
20. Koroglu A, Demirbilek S, Teksan H, Sagir O, But AK, Ersoy MO. Sedative, haemodynamic and respiratory effects of dexmedeto-midine in children undergoing magnetic resonance imaging examination: preliminary results. Br J Anaesth 2005;94:821-4
21. Mason KP, Zurakowski D, Zgleszewski SE, Robson CD, Car-rier M, Hickey PR, Dinardo JA. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth 2008;18:403-11
22. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomi-dine in humans. Anesthesiology 2000;93:382-94
23. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intrave-nous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 1992;77:1134-42
24. Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A, Boyaci A. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth 2005;15:762-6
25. Ibacache ME, Munoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthe-sia in children. Anesth Analg 2004;98:60-3
26. Shukry M, Clyde MC, Kalarickal PL, Ramadhyani U. Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia? Paediatr Anaesth 2005;15:1098-104
27. Lazol JP, Lichtenstein SE, Jooste EH, Shiderly D, Kudchadker NA, Tatum GH, Orr RA, Wearden PD, Morell VO, Munoz RA, Chrysostomou C. Effect of dexmedetomidine on pulmonary artery pressure after congenital cardiac surgery: a pilot study. Pediatr Crit Care Med 2010;11:589-92
28. Kallio A, Scheinin M, Koulu M, Ponkilainen R, Ruskoaho H, Viinamaki O, Scheinin H. Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic con-trol mechanisms. Clin Pharmacol Ther 1989;46:33-42
29. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med 2007;8:115-31
30. Xu H, Aibiki M, Seki K, Ogura S, Ogli K. Effects of dexme-detomidine, an alpha2-adrenoceptor agonist, on renal sympa-thetic nerve activity, blood pressure, heart rate and central venous pressure in urethane-anesthetized rabbits. J Auton Nerv Syst 1998;71:48-54
31. Drew GM, Whiting SB. Evidence for two distinct types of postsynaptic alpha-adrenoceptor in vascular smooth muscle in vivo. Br J Pharmacol 1979;67:207-15
32. Nichols AJ, Motley ED, Ruffolo RR Jr. Effect of pertussis toxin treatment on postjunctional alpha-1 and alpha-2 adrenoceptor function in the cardiovascular system of the pithed rat. J Pharmacol Exp Ther 1989;249:203-9
33. Kastner SB, Kull S, Kutter AP, Boller J, Bettschart-Wolfensberger R, Huhtinen MK. Cardiopulmonary effects of dexmedetomidine in sevoflurane- anesthetized sheep with and without nitric oxide inhalation. Am J Vet Res 2005;66:1496-502
34. Regitz V, Bossaller C, Strasser R, Schuler S, Hetzer R, Fleck E. Myocardial catecholamine content after heart transplantation. Circulation 1990;82:620-3
35. El-Ayoubi R, Gutkowska J, Regunathan S, Mukaddam-Daher S. Imidazoline receptors in the heart: characterization, distri-bution, and regulation. J Cardiovasc Pharmacol2002;39:875-83
36. Mukaddam-Daher S, Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides. Braz J Med Biol Res 2004;37:1239-45
37. Flacke WE, Flacke JW, Blow KD, McIntee DF, Bloor BC Effect of dexmedetomidine, an alpha 2-adrenergic agonist, in the isolated heart. J Cardiothorac Vasc Anesth 1992;6:418-23
38. Flacke JW, Flacke WE, Bloor BC, McIntee DF. Hemodynamic effects of dexmedetomidine, an alpha 2-adrenergic agonist, in autonomically denervated dogs. J Cardiovasc Pharmacol 1990;16:616-23
39. Hammer GB, Drover DR, Cao H, Jackson E, Williams GD, Ramamoorthy C, Van Hare GF, Niksch A, Dubin AM. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg 2008;106:79-83
40. Ingersoll-Weng E, Manecke GR Jr, Thistlethwaite PA. Dexme-detomidine and cardiac arrest. Anesthesiology 2004;100:738-9
41. Khan ZP, Munday IT, Jones RM, Thornton C, Mant TG, Amin D. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. Br J Anaesth 1999;83:372-80
42. Berkenbosch JW, Tobias JD. Development of bradycardia dur-ing sedation with dexmedetomidine in an infant concurrently receiving digoxin. Pediatr Crit Care Med 2003;4:203-5